WCN26-432 Relationship between social vulnerability and evolution of glomerular filtration rate in patients with polycystic kidney disease
| datacite.rights | http://purl.org/coar/access_right/c_abf2 | |
| dc.contributor.author | Arturo Dulce, Jaime | |
| dc.contributor.author | Guido Musso, Carlos | |
| dc.contributor.author | Aroca-Martinez, Gustavo | |
| dc.contributor.author | Alvarez Mora, Eveling Lisseth | |
| dc.date.accessioned | 2026-03-27T22:48:19Z | |
| dc.date.available | 2026-03-27T22:48:19Z | |
| dc.date.issued | 2026 | |
| dc.description.abstract | Polycystic kidney disease (PCD) is the main hereditary kidney disease worldwide (1). It is characterized by the progressive formation of multiple renal cysts, which increase renal volume and replace the functional parenchyma, hypertension also occurs (2). Over time, glomerular destruction impairs filtration, leading to chronic kidney disease and the need for renal replacement therapy in certain cases (3). In terms of pathophysiology, PKD is mainly associated with mutations in the PKD1 and PKD2 genes, with autosomal dominant inheritance predominating. However, there are cases without mutations in these genes, affecting other loci conditioning an earlier and more severe presentation of the disease (4). PKD is a multisystem pathology with extra-renal cystic and non-cystic manifestations. The former include brain, liver, and gastrointestinal cysts. Non-cystic manifestations include aortic and cerebral aneurysms, heart valve abnormalities, colonic diverticula, and abdominal hernias (5)(6). The most frequent clinical manifestations, related to pathophysiology, are back pain, hematuria, urinary tract infections and lithiasis (7). Globally, an estimated 12 million people suffer from ERP, with approximately 600,000 cases in the United States (8). In the European Union, prevalence ranges from 2.41 to 3.89 cases per 10,000 population, and about 91.1 cases per million people require replacement therapy due to PKD (9). In Colombia, information is limited; the former Social Security Institute reported a prevalence of 4.6% in patients with stage 4 chronic kidney disease (10). In the context of chronic kidney disease, social vulnerability acts as a determining factor that significantly increases the risk of clinical decompensation, delay in diagnosis, limited access to appropriate treatments and, consequently, a higher mortality rate (11). The objective of this study was to make a correlation between ERP and the social vulnerability score (SOVI). | eng |
| dc.format.mimetype | ||
| dc.identifier.doi | https://doi.org/10.1016/j.ekir.2026.105988 | |
| dc.identifier.issn | 24680249 (electrónico) | |
| dc.identifier.uri | https://hdl.handle.net/20.500.12442/17488 | |
| dc.identifier.url | https://www.kireports.org/article/S2468-0249(26)02219-9/fulltext | |
| dc.language.iso | eng | |
| dc.publisher | International Society of Nephrology ISN | eng |
| dc.rights | Attribution-NonCommercial-NoDerivatives 4.0 International | eng |
| dc.rights.accessrights | info:eu-repo/semantics/openAccess | |
| dc.rights.uri | http://creativecommons.org/licenses/by-nc-nd/4.0/ | |
| dc.source | Kidney Internacional Reports | eng |
| dc.source | Kireports | eng |
| dc.source | Vol. 11 No.4 (suplemento) Año 2026 | spa |
| dc.title | WCN26-432 Relationship between social vulnerability and evolution of glomerular filtration rate in patients with polycystic kidney disease | eng |
| dc.type.driver | info:eu-repo/semantics/article | |
| dc.type.spa | Artículo científico | |
| oaire.version | info:eu-repo/semantics/publishedVersion | |
| sb.sede | Sede Barranquilla | spa |